Roche: FDA grants priority review to skin condition drug

(CercleFinance.com) - The FDA has granted a priority review for Roche's MabThera/Rituxan for the treatment of pemphigus vulgaris, a rare condition characterised by painful blistering of the skin and mucous membranes, the Swiss drugmaker said.


There are currently only limited approved treatment options available for this potentially life-threatening disease, Roche said in a statement.

MabThera/Rituxan is already approved to treat rheumatoid arthritis.

Copyright (c) 2018 CercleFinance.com. All rights reserved.